Shanghai Jun is bio science co., Ltd.
This open-label phase I clinical study with clinical development phase will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS002 combined with Toripalimab in advanced cancer patients, who has failed standard therapy OR could not tolerate standard therapy OR refused/had no standard therapy. This study is divided into two parts: Part A. JS002 combined with Toripalimab dose escalation and dose expansion phase; Part B.JS002 combined with Toripalimab clinical expansion phase.
Advanced Cancer
JS001(Toripalimab)+JS002
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 9 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Recombinant Humanized Anti-PCSK9 Monoclonal Antibody (JS002) Combined With Toripalimab in Patients With Advanced Cancer |
Actual Study Start Date : | February 10, 2022 |
Estimated Primary Completion Date : | November 10, 2023 |
Estimated Study Completion Date : | November 10, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: JS001(Toripalimab)+JS002 |
Drug: JS001(Toripalimab)+JS002 |
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Henan Tumor Hospital
Zhengzhou, Henan, China, 450003